Mylan Inc (MYL)
Price: $22.98
Industry: Drugs Chaikin Power Gauge Report | Generated: Mon Mar 26 12:22 EDT 2012 Power Gauge Rating
MYL - Bullish TM
The Chaikin Power Gauge Rating for MYL is bullish due to very strong earnings performance and bullish price/volume activity. The rating also reflects negative expert opinions. MYL's earnings performance is very strong as a result of an upward trend in earnings this year and a relatively low projected P/E ratio.
News Sentiment Rating
Bullish MYL Mylan Inc
March 21, 2012
TM
Chaikin Sentiment Gauge for MYL is bullish. There is currently a significant positive sentiment within news stories concerning MYL.
News Sentiment :Positive
Power Trend - 5 Year Chart
The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
High Potential
Neutral
Low Potential
www.chaikinpowertools.com
Financials & Earnings
Financial Metrics Rating
Financial Metrics
Neutral
LT Debt/Equity Ratio
MYL's financial metrics are neutral. The company has high revenue per share and is carrying too much long term debt relative to its industry group.
Price to Book Value
The rank is based on a high long term debt to equity ratio relative to its industry group, high price to book value ratio, high return on equity, low price to sales ratio and relatively low cash flow.
Return on Equity
Price to Sales Ratio
Business Value
Assets and Liabilities
Valuation
Returns
Ratio
TTM
Ratio
TTM
Ratio
Current Ratio
1.39
Price/Book
2.80
Return on Invest
10.6%
LT Debt/Equity
1.38
Price/Sales
1.60
Return on Equity
24.2%
Earnings Performance
TTM
Earnings Performance Rating
Very Bullish
Earnings Growth
MYL's earnings performance has been very strong. The company experienced superior earnings growth in the past 12 months and is priced relatively low compared to next year's projected EPS.
Earnings Surprise
Earnings Trend
The rank is based on an upward trend in earnings this year, a relatively low projected P/E ratio and consistent earnings over the past 5 years.
Projected P/E Ratio
Earnings Consistency
5 Year Revenue and Earnings Growth
Revenue(M) Rev % Growth EPS EPS % Growth
EPS Estimates
12/07
12/08
12/09
12/10
12/11
2,666.02
5,137.58
5,092.78
5,450.52
6,129.82
65.40%
92.71%
-0.87%
7.02%
12.46%
$-4.91
$-1.05
$0.31
$0.69
$1.25
-586.14%
78.62%
129.52%
122.58%
81.16%
EPS Surprise
Factor
Actual EPS Prev
EST EPS Current
Change
$0.24
$0.52
+0.28
Quarterly EPS Yearly EPS Factor
$1.25
$2.44
+1.19
Actual EPS Growth
Est EPS Growth
Change
35.35%
9.51%
-25.84
3-5 year EPS
EPS Quarterly Results Estimate
Actual
Difference
% Difference
FY
Qtr 1
Qtr 2
Qtr 3
Qtr 4
Total
Latest Qtr
$0.50
$0.53
$0.03
1 Qtr Ago
$0.51
$0.55
$0.04
6.00
12/09
$0.23
$0.19
$-0.13
$0.01
$0.30
7.84
12/10
$0.20
$0.17
$0.35
$0.01
$0.73
2 Qtr Ago
$0.45
$0.52
3 Qtr Ago
$0.44
$0.44
$0.07
15.56
12/11
$0.24
$0.34
$0.37
$0.30
$1.25
$0.00
0.00
Fiscal Year End Month is December.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
www.chaikinpowertools.com
Price Trend & Expert Opinions Price/Volume Activity
Price/Volume Activity Rating
Bullish
Relative Strength vs Market
Price and volume activity for MYL is bullish. MYL is experiencing sustained buying and has outperformed the S&P 500 over 26 weeks.
Chaikin Money Flow
Price Trend
The rank for MYL is based on positive Chaikin money flow.
Price Trend ROC
Volume Trend
Relative Strength vs S&P500 Index
Chaikin Money Flow
Chart shows whether MYL is performing better or worse than the market.
Chaikin Money Flow analyzes supply and demand for a company's stock.
Price Activity
Price Activity
Volume Activity
Factor
Value
Factor
52 Week High
25.23
% Change Price - 4 Weeks
-3.00%
Average Volume 20 Days
5,238,400
52 Week Low
16.16
% Change Price - 24 Weeks
31.01%
Average Volume 90 Days
5,543,251
% Change Price - 4 Wks Rel to S&P
-5.33%
Chaikin Money Flow Persistency
% Change Price - 24 Wks Rel to S&P
9.25%
% Change YTD Rel S&P 500
-4.47%
Expert Opinions
Value
Factor
Value
69%
Expert Opinions
Bearish
Earnings Estimate Revisions
Expert opinions about MYL are negative. Analysts's opinions on MYL have been more negative recently and short interest in MYL is high.
Short Interest
Insider Activity
The rank for MYL is based on analysts revising earnings estimates upward, a high short interest ratio, insiders purchasing stock, pessimistic analyst opinions and relative weakness of the stock versus the Drugs industry group.
Analyst Opinions
Relative Strength vs Industry
Earnings Estimate Revisions Current Current Qtr Next Qtr
0.52 0.58 Current
Current FY
2.44
Analyst Recommendations
7 Days Ago % Change 0.52 0.58
0.00% 0.00%
30 Days Ago % Change 2.43
0.01
Factor Mean this Week Mean Last Week
EPS Estimates Revision Summary Value
Buy 0.00
Mean 5 Weeks Ago
Buy
Last 4 Weeks
Down
Up
Down
Curr Qtr
0
1
0
3
Curr Yr
0
0
1
0
Next Qtr
1
0
1
2
Next Yr
0
0
2
0
Buy
Change
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
Last Week Up
www.chaikinpowertools.com
The Company & Its Competitors
News Headlines for MYL
MYL's Competitors in Drugs Company
Power Gauge
Historic EPS growth
Projected EPS growth
Profit Margin
PEG
PE
Revenue(M)
MYL
35.35%
9.51%
8.76%
0.99
11.26
6,130
IPXL
50.69%
15.61%
12.77%
0.86
24.09
513
WPI
18.82%
8.68%
5.69%
1.31
13.70
4,584
TEVA
16.94%
8.40%
15.07%
0.92
8.65
18,312
PRX
12.80%
7.76%
-2.82%
1.35
11.20
926
RDY
38.12%
25.00%
15.63%
0.70
19.28
1,677
SCR
14.96%
5.17%
8.74%
3.94
21.51
324
HITK
24.65%
-
22.59%
-
9.20
191
BRIEF: Mylan receives approval for generic Boniva - Mar 21, 2012 Mylan One of First to Launch Generic Version of Boniva® - Mar 20, 2012 Mylan Canada Receives Health Canada Approval for Generic Version of Crestor® - Mar 15, 2012 Mylan Launches First Equivalent Product to Lexapro® Tablets - Feb 29, 2012 Mylan Receives Tentative FDA Approval Through PEPFAR for Pediatric HIV/AIDS Therapy - Feb 23, 2012
Company Details
Company Profile
Mylan Inc 1500 CORPORATE DRIVE SUITE 400 CANONSBURG, PA 15317 USA Phone: 724-514-1800 Fax: 724-514-1870 Website: http://http://www.mylan.com Full Time Employees: 18,000 Sector: Medical
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.
LM 2.3 DS 3.0 LS 2.1
Data Provided by ZACKS Investment Research, Inc., www.zacks.com
Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com